Brokerages expect that Beyond Air, Inc. (NASDAQ:XAIR – Get Rating) will report earnings per share (EPS) of ($0.24) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Beyond Air’s earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.22). Beyond Air also reported earnings per share of ($0.24) in the same quarter last year. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Beyond Air will report full year earnings of ($1.18) per share for the current fiscal year, with EPS estimates ranging from ($1.22) to ($1.15). For the next year, analysts anticipate that the business will post earnings of ($0.84) per share, with EPS estimates ranging from ($1.00) to ($0.57). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Beyond Air.
Beyond Air (NASDAQ:XAIR – Get Rating) last posted its earnings results on Thursday, February 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). During the same period last year, the firm posted ($0.33) EPS.
Shares of XAIR stock traded up $0.18 on Thursday, hitting $6.46. 805 shares of the company’s stock traded hands, compared to its average volume of 214,609. Beyond Air has a one year low of $4.62 and a one year high of $16.41. The firm’s fifty day moving average is $7.02. The stock has a market cap of $192.71 million, a PE ratio of -5.23 and a beta of -0.53.
In other Beyond Air news, Director Robert Carey bought 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 5th. The stock was bought at an average cost of $6.71 per share, for a total transaction of $134,200.00. Following the completion of the transaction, the director now owns 567,323 shares of the company’s stock, valued at approximately $3,806,737.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 43,685 shares of company stock valued at $293,447 over the last quarter. Company insiders own 11.90% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in XAIR. Morgan Stanley raised its stake in shares of Beyond Air by 25.5% in the second quarter. Morgan Stanley now owns 66,878 shares of the company’s stock valued at $433,000 after acquiring an additional 13,601 shares during the period. Secure Asset Management LLC grew its holdings in Beyond Air by 6.5% during the 3rd quarter. Secure Asset Management LLC now owns 16,384 shares of the company’s stock worth $182,000 after acquiring an additional 997 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Beyond Air by 180.6% during the 3rd quarter. Advisor Group Holdings Inc. now owns 158,672 shares of the company’s stock worth $1,765,000 after acquiring an additional 102,124 shares in the last quarter. BlackRock Inc. grew its holdings in Beyond Air by 74.4% during the 3rd quarter. BlackRock Inc. now owns 98,539 shares of the company’s stock worth $1,096,000 after acquiring an additional 42,052 shares in the last quarter. Finally, Wolverine Trading LLC lifted its position in shares of Beyond Air by 80.4% during the third quarter. Wolverine Trading LLC now owns 20,120 shares of the company’s stock valued at $217,000 after buying an additional 8,970 shares during the last quarter. 15.63% of the stock is currently owned by institutional investors and hedge funds.
About Beyond Air (Get Rating)
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors.
- Get a free copy of the StockNews.com research report on Beyond Air (XAIR)
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.